LPL and diffuse large B-cell lymphoma: Nonetheless, our results are in line with the previously reported activity of emavusertib in MYD88 L265P mutated ABC DLBCL cell lines [26], and they indicate that emavusertib as single agent could be explored in the population of patients with MYD88 mutated LPL or MZL.